[go: up one dir, main page]

WO2008099608A1 - 炎症性腸疾患の診断方法 - Google Patents

炎症性腸疾患の診断方法 Download PDF

Info

Publication number
WO2008099608A1
WO2008099608A1 PCT/JP2008/000222 JP2008000222W WO2008099608A1 WO 2008099608 A1 WO2008099608 A1 WO 2008099608A1 JP 2008000222 W JP2008000222 W JP 2008000222W WO 2008099608 A1 WO2008099608 A1 WO 2008099608A1
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
bowel disease
diagnosis
activity
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/000222
Other languages
English (en)
French (fr)
Inventor
Shingo Kato
Koji Yakabi
Yukio Ito
Mina Sagara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saitama Medical University
Perseus Proteomics Inc
Original Assignee
Saitama Medical University
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saitama Medical University, Perseus Proteomics Inc filed Critical Saitama Medical University
Priority to JP2008558008A priority Critical patent/JP5280214B2/ja
Publication of WO2008099608A1 publication Critical patent/WO2008099608A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

　炎症性腸疾患の有無、および／または炎症性腸疾患の活動性の診断方法の提供。 　被検試料中のＰＴＸ３を測定することを特徴とする、炎症性腸疾患の有無および／または炎症性腸疾患の活動性判定方法。
PCT/JP2008/000222 2007-02-15 2008-02-14 炎症性腸疾患の診断方法 Ceased WO2008099608A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008558008A JP5280214B2 (ja) 2007-02-15 2008-02-14 炎症性腸疾患の診断方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034233 2007-02-15
JP2007-034233 2007-02-15

Publications (1)

Publication Number Publication Date
WO2008099608A1 true WO2008099608A1 (ja) 2008-08-21

Family

ID=39689855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000222 Ceased WO2008099608A1 (ja) 2007-02-15 2008-02-14 炎症性腸疾患の診断方法

Country Status (2)

Country Link
JP (1) JP5280214B2 (ja)
WO (1) WO2008099608A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011254810A (ja) * 2010-05-12 2011-12-22 En Otsuka Pharmaceutical Co Ltd クローン病の活動性の分類
JP2012053034A (ja) * 2010-08-06 2012-03-15 Perseus Proteomics Inc 炎症状態の検出方法
WO2019056991A1 (zh) * 2017-09-19 2019-03-28 臻崴生物科技有限公司 单克隆抗体或其抗原结合片段及其用途
US12152070B2 (en) 2018-09-14 2024-11-26 Ohealth Biopharmaceutical (Suzhou) Co., Ltd. Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof
WO2025013850A1 (ja) * 2023-07-12 2025-01-16 株式会社島津製作所 消化管の粘膜における障害の判定方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005106494A2 (en) * 2004-04-29 2005-11-10 Farma Development S.R.L. Monoclonal antibodies, hybridomas, improved method for determining the protein ptx3 and kit for said determination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005106494A2 (en) * 2004-04-29 2005-11-10 Farma Development S.R.L. Monoclonal antibodies, hybridomas, improved method for determining the protein ptx3 and kit for said determination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OKUTANI D.: "Atarashii Mediator Pentraxin3 no Ensho Hanno ni Okeru Yakuwari", JPN. J. IMMUNOL., vol. 29, no. 3, 2006, pages 107 - 113, XP003020687 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011254810A (ja) * 2010-05-12 2011-12-22 En Otsuka Pharmaceutical Co Ltd クローン病の活動性の分類
JP2012053034A (ja) * 2010-08-06 2012-03-15 Perseus Proteomics Inc 炎症状態の検出方法
WO2019056991A1 (zh) * 2017-09-19 2019-03-28 臻崴生物科技有限公司 单克隆抗体或其抗原结合片段及其用途
US12152070B2 (en) 2018-09-14 2024-11-26 Ohealth Biopharmaceutical (Suzhou) Co., Ltd. Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof
WO2025013850A1 (ja) * 2023-07-12 2025-01-16 株式会社島津製作所 消化管の粘膜における障害の判定方法

Also Published As

Publication number Publication date
JPWO2008099608A1 (ja) 2010-05-27
JP5280214B2 (ja) 2013-09-04

Similar Documents

Publication Publication Date Title
WO2010025393A3 (en) Protein biomarkers and methods for diagnosing kawasaki disease
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
WO2011072177A3 (en) Biomarker assay for diagnosis and classification of cardiovascular disease
WO2008008284A3 (en) Cancer biomarkers and methods of use threof
WO2007127749A3 (en) Predicting mortality and detecting severe disease
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
IL185477A0 (en) Diagnostic methods and systems based on urine analysis
WO2005114190A3 (en) Methods of identifying biomarkers
WO2008131361A3 (en) Biosensors for measuring analytes in the interstitial fluid
WO2009134944A3 (en) Methods of determining the health status of an individual
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2009085356A8 (en) Methods of using and constructing nanosensor platforms
WO2008106648A3 (en) Immunoassays exhibiting a reduction in prozone phenomena
PL1977225T3 (pl) Elektrochemiczny bioczujnikowy układ analityczny
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2010045490A3 (en) Human biomarker hypermapping for depressive disorders
WO2008027098A3 (en) Biosensor for measurement of species in a body fluid
WO2011021041A3 (en) Survival prognostic assay
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2075341A4 (en) METHOD FOR THE INVESTIGATION, DETERMINATION OR EVALUATION BY MEANS OF GENE EXPRESSION ANALYSIS
WO2010046648A3 (en) Diagnostic test for streptococcus equi
WO2010090834A3 (en) Netrin-1 as a biomarker of injury and disease
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2009007649A3 (fr) Dispositif et procede d'identification et de determination de groupes sanguins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710376

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008558008

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08710376

Country of ref document: EP

Kind code of ref document: A1